T2 Biosystems

About T2 Biosystems

T2 Biosystems, Inc. is an in-vitro diagnostics company established in 2006, originating from technology developed at the Massachusetts Institute of Technology (MIT). The company was founded by a team that includes Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder. The firm focuses on the rapid detection of sepsis-causing pathogens and antibiotic resistance genes.

The company's business model follows the classic razor-and-blade strategy, generating revenue from the initial sale of its T2Dx® Instruments and the recurring sales of associated test panels. This approach ensures ongoing revenue from consumable panels used by its client base, which primarily consists of hospitals and healthcare facilities. To expand its market reach, T2 Biosystems utilizes distribution agreements with partners like Cardinal Health and engages with group purchasing organizations (GPOs) such as Vizient. The company is also exploring a strategy to license its intellectual property to other diagnostic firms, aiming to create non-dilutive capital and royalty revenue streams.

T2 Biosystems' core offering is its proprietary T2 Magnetic Resonance (T2MR®) technology. This platform enables the direct detection of pathogens from a whole blood sample, eliminating the need for time-consuming blood cultures which can take days to yield results. The T2MR process works by introducing superparamagnetic particles coated with target-specific binding agents into a blood sample. If pathogens are present, these particles cluster around them, altering the magnetic properties of the surrounding water molecules, which is then detected by the T2Dx® Instrument. This method delivers results in just 3 to 5 hours, a significant reduction in time compared to traditional methods.

The product portfolio includes several FDA-cleared diagnostic panels that run on the T2Dx® Instrument. The T2Candida® Panel detects fungal infections, the T2Bacteria® Panel identifies common sepsis-causing bacteria, and the T2Biothreat™ Panel simultaneously screens for six high-priority biothreat pathogens. The company has received multiple FDA clearances, including for its T2Dx Instrument and T2Candida Panel in 2014, the T2Bacteria Panel in 2018, the T2Biothreat Panel in 2023, and an expansion of the T2Bacteria Panel in 2024. T2 Biosystems went public with an IPO on the Nasdaq in August 2014.